ATC Code: V09AX04 On October 25 th , the FDA approved Flutemetamol F18 (Tradename: Vizamyl ; Research Code: [ 18 F]AH110690 ), a radioactive diagnostic agent, for intravenous (i.v.) use in Positron Emission Tomography (PET) imaging of the brain in adult patients with cognitive impairment , who are being evaluated for Alzheimer’s disease (AD) and dementia. Alzheimer's disease is a non-treatable, progressively worsening and fatal disease, characterised by a decrease in cognitive functions, such as memory, and is usually associated with an accumulation of β amyloid (Uniprot: P05067 ) plaques in several brain regions. These deposits are believed to be responsible for cellular damage and ultimately cell death. Flutemetamol F18 is the second approved diagnostic drug to estimate β-amyloid neuritic plaque density, after the approval of Florbetapir F18 in 2012. Like Florbetapir F18, Flutemetamol F18 binds to β amyloid plaques in the brain where the F-18 isotope produces...
The Organization of Drug Discovery Data
| | | | | | | |